Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

Steep U.S. Increase Projected For Rare Skin Cancer

(UW Medicine) Feb 16, 2018 - The number of U.S. cases of Merkel cell carcinoma, an often-fatal skin cancer, is rising about six times faster than most other cancers and at nearly twice the rate of the more-common melanoma.

NCCN Guidelines Broadly Endorse Biomarker Testing in Prostate Cancer

(Myriad Genetics) Feb 20, 2018 - Myriad Genetics, Inc. today announced that the National Comprehensive Cancer Network (NCCN) has updated its medical guidelines for prostate cancer treatment to broadly include biomarker testing in prostate cancer.

Highly Mutated Protein in Skin Cancer Plays Central Role in Skin Cell Renewal

(Penn Medicine) Feb 19, 2018 - Cells lining such organs as skin and the gut, lungs, and many other organs (collectively called epithelial tissue) rely on a delicate balance of self-renewal, proliferation, and differentiation. However, disruption of this equilibrium may drive cancer and other disorders.

TransMed Provides New Set Of Clinical Trial Technologies For Pharma, CROs, Research Networks and Oncology Providers

(Business Insider) Feb 20, 2018 - In an effort to address the challenge of clinical trial recruitment head-on, the National Cancer Care Alliance (NCCA) today announces that it has selected the TransMed Trials™ family of real-world evidence based oncology clinical trial techologies from TransMed Systems, Inc., to recommend to its member practices.

FDA Expands Approval Of Imfinzi To Reduce The Risk Of Non-small Cell Lung Cancer Progressing

(FDA.gov) Feb 16, 2018 - The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation).

Evaluating Quality of Life After Kidney Cancer Treatments

(Northwestern Medicine) Feb 16, 2018 - Patients with an advanced form of kidney cancer had similar quality of life outcomes taking a drug called cabozantinib as those who received the standard treatment, everolimus, according to a new Northwestern Medicine study. The findings were published in the Journal of Clinical Oncology.

Inaugural Content Collection in JCO Clinical Cancer Informatics Highlights the Benefits of Data Sharing in Oncology

(ASCO in Action) Feb 16, 2018 - On Feb. 16, 2018, JCO Clinical Cancer Informatics (JCO CCI) published its first special collection of articles. This collection highlights ways in which sharing cancer research data is now possible through individual networks, including ASCO’s CancerLinQ®.

March 7, 2018: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement

(FDA.gov) Feb 16, 2018 - Agenda: The committee will discuss supplemental biologic license application (sBLA) 125557/S-013, for BLINCYTO (blinatumomab) injection for intravenous use, application submitted by Amgen, Inc. The proposed indication (use) for this product is for the treatment of minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia.

Many Women Who Choose Breast Reconstruction are Less Satisfied Than Expected Post Surgery

(OSUCCC – James) Feb 19, 2018 - Many breast cancer patients undergoing mastectomy with or without immediate reconstruction mispredict future satisfaction with aspects of physical and sexual health post-surgery, according to a new study published by researchers at the OSUCCC – James.

21st Century Oncology’s New CEO Seeks To Rehab Company Image, Expand Operations

(The News-Press [Fort Myers, FL]) Feb 19, 2018 - With bankruptcy proceedings and $500 million of its debt now a memory, cancer-care giant 21st Century Oncology wants to rehabilitate its image, boost staff morale and expand its operations, the company’s new CEO said in an exclusive interview with The News-Press.